Theodosios Kyriakou1, Udo Seedorf1, Anuj Goel1, Jemma C Hopewell1, Robert Clarke1, Hugh Watkins1, Martin Farrall2. 1. From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine (T.K., A,G., H.W., M.F.), Wellcome Trust Centre for Human Genetics (T.K., A.G., H.W., M.F.), and Clinical Trial Service Unit and Epidemiological Studies Unit (J.C.H., R.C.), University of Oxford, Oxford, United Kingdom; and Leibniz-Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany (U.S.). 2. From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine (T.K., A,G., H.W., M.F.), Wellcome Trust Centre for Human Genetics (T.K., A.G., H.W., M.F.), and Clinical Trial Service Unit and Epidemiological Studies Unit (J.C.H., R.C.), University of Oxford, Oxford, United Kingdom; and Leibniz-Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany (U.S.). martin.farrall@cardiov.ox.ac.uk.
Abstract
OBJECTIVE: Increased levels of lipoprotein(a) are a highly heritable risk factor for coronary artery disease (CAD). The genetic determinants of lipoprotein(a) levels are mainly because of genetic variation in the apolipoprotein(a) gene (LPA). We have tested the association of a relatively common null allele of LPA with lipoprotein(a) levels and CAD risk in a large case-control cohort. We have also examined how null allele genotyping complements apolipoprotein(a) isoform typing to refine the relationship between LPA isoform size and circulating lipoprotein(a) levels. APPROACH AND RESULTS: The LPA null allele (rs41272114) was genotyped in the PROCARDIS (Precocious Coronary Artery Disease) case-control cohort (4073 CAD cases and 4225 controls). Lipoprotein(a) levels were measured in 909 CAD cases and 922 controls; apolipoprotein(a) isoform size was estimated using sodium dodecyl sulfate-agarose gel electrophoresis and a high-throughput quantitative polymerase chain reaction-based method. Null carriers are common (null allele frequency, 3%) and have significantly lower circulating lipoprotein(a) levels (P=2.1×10(-10)) and reduced CAD risk (odds ratio, 0.79 [0.66-0.97]; P=0.023) compared with noncarriers. An additive allelic model of apolipoprotein(a) isoform size, refined by null allele genotype and quantitative polymerase chain reaction values, showed a sigmoid relationship with lipoprotein(a) levels, with baseline levels for longer isoform alleles and progressively higher levels of lipoprotein(a) for shorter isoform alleles. CONCLUSIONS: The LPA null allele (rs41272114) is associated with decreased circulating lipoprotein(a) levels and decreased CAD risk. Incorporating rs41272114 refined apolipoprotein(a) isoform size typing obtained by immunoblotting and quantitative polymerase chain reaction. A joint genomic and isoform analysis revealed details of the relationship between apolipoprotein(a) isoform size and circulating lipoprotein(a) level consistent with a threshold effect on lipoprotein secretion.
OBJECTIVE: Increased levels of lipoprotein(a) are a highly heritable risk factor for coronary artery disease (CAD). The genetic determinants of lipoprotein(a) levels are mainly because of genetic variation in the apolipoprotein(a) gene (LPA). We have tested the association of a relatively common null allele of LPA with lipoprotein(a) levels and CAD risk in a large case-control cohort. We have also examined how null allele genotyping complements apolipoprotein(a) isoform typing to refine the relationship between LPA isoform size and circulating lipoprotein(a) levels. APPROACH AND RESULTS: The LPA null allele (rs41272114) was genotyped in the PROCARDIS (Precocious Coronary Artery Disease) case-control cohort (4073 CAD cases and 4225 controls). Lipoprotein(a) levels were measured in 909 CAD cases and 922 controls; apolipoprotein(a) isoform size was estimated using sodium dodecyl sulfate-agarose gel electrophoresis and a high-throughput quantitative polymerase chain reaction-based method. Null carriers are common (null allele frequency, 3%) and have significantly lower circulating lipoprotein(a) levels (P=2.1×10(-10)) and reduced CAD risk (odds ratio, 0.79 [0.66-0.97]; P=0.023) compared with noncarriers. An additive allelic model of apolipoprotein(a) isoform size, refined by null allele genotype and quantitative polymerase chain reaction values, showed a sigmoid relationship with lipoprotein(a) levels, with baseline levels for longer isoform alleles and progressively higher levels of lipoprotein(a) for shorter isoform alleles. CONCLUSIONS: The LPA null allele (rs41272114) is associated with decreased circulating lipoprotein(a) levels and decreased CAD risk. Incorporating rs41272114 refined apolipoprotein(a) isoform size typing obtained by immunoblotting and quantitative polymerase chain reaction. A joint genomic and isoform analysis revealed details of the relationship between apolipoprotein(a) isoform size and circulating lipoprotein(a) level consistent with a threshold effect on lipoprotein secretion.
Authors: Connor A Emdin; Amit V Khera; Pradeep Natarajan; Derek Klarin; Hong-Hee Won; Gina M Peloso; Nathan O Stitziel; Akihiro Nomura; Seyedeh M Zekavat; Alexander G Bick; Namrata Gupta; Rosanna Asselta; Stefano Duga; Piera Angelica Merlini; Adolfo Correa; Thorsten Kessler; James G Wilson; Matthew J Bown; Alistair S Hall; Peter S Braund; Nilesh J Samani; Heribert Schunkert; Jaume Marrugat; Roberto Elosua; Ruth McPherson; Martin Farrall; Hugh Watkins; Cristen Willer; Gonçalo R Abecasis; Janine F Felix; Ramachandran S Vasan; Eric Lander; Daniel J Rader; John Danesh; Diego Ardissino; Stacey Gabriel; Danish Saleheen; Sekar Kathiresan Journal: J Am Coll Cardiol Date: 2016-12-27 Impact factor: 24.094
Authors: Terry Solomon; Erin N Smith; Hiroko Matsui; Sigrid K Braekkan; Tom Wilsgaard; Inger Njølstad; Ellisiv B Mathiesen; John-Bjarne Hansen; Kelly A Frazer Journal: Circ Cardiovasc Genet Date: 2016-06-21
Authors: Salome Mack; Stefan Coassin; Rico Rueedi; Noha A Yousri; Ilkka Seppälä; Christian Gieger; Sebastian Schönherr; Lukas Forer; Gertraud Erhart; Pedro Marques-Vidal; Janina S Ried; Gerard Waeber; Sven Bergmann; Doreen Dähnhardt; Andrea Stöckl; Olli T Raitakari; Mika Kähönen; Annette Peters; Thomas Meitinger; Konstantin Strauch; Ludmilla Kedenko; Bernhard Paulweber; Terho Lehtimäki; Steven C Hunt; Peter Vollenweider; Claudia Lamina; Florian Kronenberg Journal: J Lipid Res Date: 2017-05-16 Impact factor: 5.922